Atlas Trials

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD

Clinical trial NCT07222553 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07222553
Sponsor
Amgen
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Immunoglobulin G4-related Disease
Start date
2026-07-31
Primary completion
2031-06-10
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.